| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 119 | 2024 | 11538 | 6.930 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 73 | 2023 | 5319 | 5.990 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 12 | 2023 | 159 | 2.710 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 5 | 2022 | 371 | 2.700 |
Why?
|
| Epithelial-Mesenchymal Transition | 24 | 2023 | 973 | 2.690 |
Why?
|
| Tumor Microenvironment | 28 | 2023 | 2864 | 2.090 |
Why?
|
| Golgi Apparatus | 6 | 2022 | 147 | 2.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 14 | 2023 | 1331 | 1.870 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2023 | 5178 | 1.720 |
Why?
|
| B7-H1 Antigen | 18 | 2023 | 1022 | 1.580 |
Why?
|
| Neoplasm Metastasis | 24 | 2022 | 5112 | 1.520 |
Why?
|
| MicroRNAs | 15 | 2023 | 2947 | 1.490 |
Why?
|
| Cell Line, Tumor | 49 | 2023 | 14551 | 1.440 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2019 | 141 | 1.340 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2023 | 1249 | 1.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2022 | 1586 | 1.210 |
Why?
|
| Mutation | 33 | 2023 | 15179 | 1.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 24 | 2023 | 8873 | 1.140 |
Why?
|
| Extracellular Matrix | 6 | 2020 | 554 | 1.000 |
Why?
|
| Immunotherapy | 13 | 2023 | 3341 | 1.000 |
Why?
|
| Neoplasm Invasiveness | 9 | 2022 | 3981 | 0.960 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 2 | 2023 | 28 | 0.950 |
Why?
|
| Matrix Metalloproteinases | 2 | 2020 | 143 | 0.900 |
Why?
|
| Adenocarcinoma | 23 | 2023 | 7789 | 0.880 |
Why?
|
| Neoplasms | 14 | 2022 | 15193 | 0.880 |
Why?
|
| Mice | 46 | 2023 | 34495 | 0.880 |
Why?
|
| Vesicular Transport Proteins | 2 | 2021 | 135 | 0.860 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2021 | 28 | 0.810 |
Why?
|
| Humans | 133 | 2024 | 261506 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 15862 | 0.770 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2023 | 4757 | 0.770 |
Why?
|
| ErbB Receptors | 18 | 2023 | 2295 | 0.770 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.750 |
Why?
|
| Cell Movement | 14 | 2023 | 2466 | 0.730 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 3552 | 0.730 |
Why?
|
| Endocytosis | 2 | 2019 | 225 | 0.720 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 661 | 0.710 |
Why?
|
| Animals | 52 | 2023 | 59536 | 0.710 |
Why?
|
| Th17 Cells | 1 | 2021 | 162 | 0.710 |
Why?
|
| Collagen | 2 | 2020 | 752 | 0.700 |
Why?
|
| Genes, src | 1 | 2019 | 27 | 0.690 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2019 | 20 | 0.690 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2020 | 243 | 0.690 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 126 | 0.680 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2014 | 1094 | 0.670 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.660 |
Why?
|
| Cathepsins | 1 | 2018 | 46 | 0.650 |
Why?
|
| Membrane Proteins | 8 | 2023 | 2819 | 0.630 |
Why?
|
| Cadherins | 2 | 2019 | 660 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 4367 | 0.580 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2488 | 0.570 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 246 | 0.560 |
Why?
|
| Gene Expression Profiling | 13 | 2022 | 5159 | 0.550 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 4975 | 0.530 |
Why?
|
| Integrin beta1 | 1 | 2016 | 126 | 0.520 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 1491 | 0.510 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2016 | 161 | 0.510 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2021 | 406 | 0.510 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 1756 | 0.510 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 1265 | 0.510 |
Why?
|
| Gene Knockdown Techniques | 6 | 2020 | 1077 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2021 | 3821 | 0.490 |
Why?
|
| Signal Transduction | 20 | 2023 | 11965 | 0.480 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 7222 | 0.480 |
Why?
|
| Pyridazines | 2 | 2014 | 293 | 0.480 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 6 | 2023 | 992 | 0.470 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2023 | 1048 | 0.460 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 1073 | 0.460 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2020 | 1062 | 0.420 |
Why?
|
| Biomarkers, Tumor | 16 | 2023 | 10331 | 0.420 |
Why?
|
| Epithelial Cells | 5 | 2021 | 1818 | 0.400 |
Why?
|
| Models, Molecular | 3 | 2014 | 1732 | 0.390 |
Why?
|
| Cell Culture Techniques | 4 | 2019 | 598 | 0.390 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 2527 | 0.390 |
Why?
|
| Imidazoles | 2 | 2014 | 999 | 0.390 |
Why?
|
| Disease Progression | 7 | 2023 | 6682 | 0.380 |
Why?
|
| Transcriptome | 8 | 2023 | 1859 | 0.380 |
Why?
|
| Genomics | 10 | 2023 | 2738 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 1439 | 0.360 |
Why?
|
| Extracellular Space | 1 | 2009 | 132 | 0.350 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2021 | 107 | 0.340 |
Why?
|
| Nuclear Proteins | 3 | 2023 | 3343 | 0.340 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2023 | 1016 | 0.330 |
Why?
|
| Pyrimidines | 6 | 2023 | 3518 | 0.330 |
Why?
|
| Interleukin-2 | 2 | 2022 | 842 | 0.320 |
Why?
|
| Benzimidazoles | 3 | 2021 | 428 | 0.320 |
Why?
|
| Datasets as Topic | 2 | 2020 | 181 | 0.320 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 235 | 0.320 |
Why?
|
| Drug Synergism | 3 | 2021 | 1313 | 0.310 |
Why?
|
| DNA Damage | 5 | 2020 | 1954 | 0.310 |
Why?
|
| Melanoma | 3 | 2023 | 5317 | 0.300 |
Why?
|
| Immunohistochemistry | 7 | 2021 | 7548 | 0.300 |
Why?
|
| Cell Proliferation | 8 | 2021 | 7226 | 0.300 |
Why?
|
| Fibroblasts | 4 | 2018 | 1682 | 0.290 |
Why?
|
| Lung | 9 | 2023 | 3151 | 0.290 |
Why?
|
| Ipilimumab | 5 | 2023 | 710 | 0.280 |
Why?
|
| Female | 38 | 2023 | 141928 | 0.280 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 3230 | 0.280 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 3869 | 0.280 |
Why?
|
| Quinazolines | 4 | 2022 | 923 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 2 | 2021 | 848 | 0.270 |
Why?
|
| Inflammation | 1 | 2016 | 2522 | 0.270 |
Why?
|
| Male | 32 | 2023 | 123000 | 0.270 |
Why?
|
| Prognosis | 13 | 2024 | 21713 | 0.270 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2020 | 315 | 0.260 |
Why?
|
| Smoking | 2 | 2016 | 2440 | 0.260 |
Why?
|
| Benzamides | 3 | 2019 | 1832 | 0.260 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 1058 | 0.260 |
Why?
|
| Semliki forest virus | 1 | 2003 | 6 | 0.240 |
Why?
|
| Acrylamides | 1 | 2023 | 53 | 0.230 |
Why?
|
| Mutation, Missense | 1 | 2009 | 1152 | 0.230 |
Why?
|
| Amino Acid Oxidoreductases | 2 | 2020 | 24 | 0.230 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2023 | 31 | 0.230 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2023 | 80 | 0.230 |
Why?
|
| Ataxia Telangiectasia | 1 | 2023 | 62 | 0.230 |
Why?
|
| Aged | 24 | 2023 | 70117 | 0.230 |
Why?
|
| A549 Cells | 2 | 2021 | 124 | 0.230 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 14289 | 0.230 |
Why?
|
| Synaptotagmins | 1 | 2022 | 11 | 0.220 |
Why?
|
| Protein Transport | 2 | 2022 | 734 | 0.220 |
Why?
|
| Piperazines | 4 | 2019 | 2101 | 0.220 |
Why?
|
| Cell Death | 2 | 2023 | 671 | 0.220 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2014 | 270 | 0.210 |
Why?
|
| Mice, Knockout | 3 | 2021 | 5710 | 0.210 |
Why?
|
| Acetylation | 1 | 2023 | 508 | 0.210 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 105 | 0.200 |
Why?
|
| Genes, erbB | 1 | 2021 | 26 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2019 | 5395 | 0.200 |
Why?
|
| Histamine | 1 | 2021 | 53 | 0.200 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 566 | 0.200 |
Why?
|
| Aged, 80 and over | 11 | 2023 | 29902 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2022 | 69 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 199 | 0.200 |
Why?
|
| Benzocycloheptenes | 1 | 2021 | 10 | 0.200 |
Why?
|
| CTLA-4 Antigen | 2 | 2023 | 657 | 0.200 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 35 | 0.200 |
Why?
|
| Arthritis | 1 | 2022 | 139 | 0.200 |
Why?
|
| Exons | 2 | 2022 | 1328 | 0.200 |
Why?
|
| Protein Binding | 2 | 2019 | 3438 | 0.190 |
Why?
|
| Glucosyltransferases | 1 | 2021 | 54 | 0.190 |
Why?
|
| CD3 Complex | 1 | 2022 | 314 | 0.190 |
Why?
|
| Survival Analysis | 7 | 2021 | 9180 | 0.190 |
Why?
|
| 5'-Nucleotidase | 1 | 2021 | 61 | 0.190 |
Why?
|
| CD8 Antigens | 1 | 2021 | 170 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 54 | 0.190 |
Why?
|
| CD4 Antigens | 1 | 2021 | 170 | 0.190 |
Why?
|
| Middle Aged | 21 | 2023 | 86204 | 0.190 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2020 | 35 | 0.190 |
Why?
|
| Indoles | 2 | 2023 | 1009 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 788 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 4 | 2016 | 1130 | 0.190 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 59 | 0.190 |
Why?
|
| Homeodomain Proteins | 3 | 2014 | 1143 | 0.180 |
Why?
|
| CD40 Antigens | 1 | 2020 | 104 | 0.180 |
Why?
|
| Neoplasms, Experimental | 2 | 2021 | 750 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.180 |
Why?
|
| Mice, Inbred Strains | 1 | 2021 | 521 | 0.180 |
Why?
|
| Bites and Stings | 1 | 2020 | 44 | 0.180 |
Why?
|
| HLA Antigens | 2 | 2021 | 546 | 0.180 |
Why?
|
| Cell Membrane | 1 | 2003 | 850 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2023 | 430 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 126 | 0.170 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2019 | 73 | 0.170 |
Why?
|
| Co-Repressor Proteins | 1 | 2019 | 122 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 129 | 0.170 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2023 | 803 | 0.170 |
Why?
|
| Phthalazines | 2 | 2019 | 253 | 0.170 |
Why?
|
| Immunomodulation | 2 | 2018 | 242 | 0.170 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 25 | 0.170 |
Why?
|
| GATA Transcription Factors | 1 | 2018 | 19 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 545 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 155 | 0.160 |
Why?
|
| Oncogenes | 3 | 2022 | 673 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2023 | 674 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 327 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.160 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2018 | 94 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2023 | 1038 | 0.160 |
Why?
|
| Imatinib Mesylate | 2 | 2014 | 1665 | 0.160 |
Why?
|
| Proteomics | 4 | 2020 | 1380 | 0.160 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 222 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 1226 | 0.160 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 771 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 833 | 0.160 |
Why?
|
| Interferon-gamma | 2 | 2021 | 1144 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 1555 | 0.160 |
Why?
|
| Exocytosis | 1 | 2018 | 111 | 0.160 |
Why?
|
| Pneumonia | 1 | 2023 | 751 | 0.150 |
Why?
|
| Immune Tolerance | 2 | 2021 | 403 | 0.150 |
Why?
|
| Research Design | 2 | 2020 | 1544 | 0.150 |
Why?
|
| Serine Proteases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Mesoderm | 1 | 2019 | 404 | 0.150 |
Why?
|
| Receptors, Notch | 2 | 2011 | 383 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2021 | 649 | 0.150 |
Why?
|
| Leucine | 1 | 2018 | 352 | 0.140 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2014 | 131 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2023 | 1216 | 0.140 |
Why?
|
| Adult | 13 | 2023 | 77950 | 0.140 |
Why?
|
| Claudins | 1 | 2016 | 47 | 0.140 |
Why?
|
| Microscopy | 1 | 2017 | 182 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.140 |
Why?
|
| Proteolysis | 1 | 2018 | 370 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 2017 | 170 | 0.140 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 229 | 0.140 |
Why?
|
| Cisplatin | 3 | 2020 | 2432 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2020 | 1489 | 0.140 |
Why?
|
| Antigen Presentation | 1 | 2017 | 272 | 0.140 |
Why?
|
| Focal Adhesions | 1 | 2016 | 45 | 0.140 |
Why?
|
| RNA Interference | 3 | 2016 | 1408 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1033 | 0.140 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 292 | 0.140 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 4143 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2018 | 842 | 0.140 |
Why?
|
| Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 1 | 2015 | 23 | 0.140 |
Why?
|
| Lysosomes | 1 | 2018 | 347 | 0.130 |
Why?
|
| Tumor Burden | 5 | 2021 | 1987 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1910 | 0.130 |
Why?
|
| Tretinoin | 1 | 2018 | 623 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 835 | 0.130 |
Why?
|
| B7 Antigens | 1 | 2016 | 84 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 713 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 3 | 2021 | 2518 | 0.130 |
Why?
|
| Receptors, Progesterone | 2 | 2021 | 1392 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 188 | 0.130 |
Why?
|
| Mesothelioma | 1 | 2020 | 544 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 1146 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2016 | 204 | 0.130 |
Why?
|
| Retrospective Studies | 12 | 2023 | 37905 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1294 | 0.120 |
Why?
|
| Transcription Factors | 4 | 2023 | 5270 | 0.120 |
Why?
|
| DNA Primers | 2 | 2014 | 1399 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2021 | 4307 | 0.120 |
Why?
|
| Survival Rate | 4 | 2021 | 12221 | 0.120 |
Why?
|
| DNA Methylation | 3 | 2020 | 2669 | 0.120 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2013 | 9 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 810 | 0.120 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 104 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 14889 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 1547 | 0.110 |
Why?
|
| Models, Biological | 2 | 2019 | 3254 | 0.110 |
Why?
|
| Rats | 3 | 2019 | 6086 | 0.110 |
Why?
|
| Cohort Studies | 6 | 2022 | 9244 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 1879 | 0.110 |
Why?
|
| Actin Cytoskeleton | 1 | 2012 | 82 | 0.110 |
Why?
|
| Cellular Microenvironment | 1 | 2012 | 41 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2018 | 2450 | 0.100 |
Why?
|
| Hydrogels | 1 | 2012 | 123 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2021 | 5437 | 0.100 |
Why?
|
| Calcium | 1 | 2018 | 1537 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.100 |
Why?
|
| Cloning, Molecular | 1 | 2014 | 1213 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 673 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2023 | 249 | 0.100 |
Why?
|
| Mice, 129 Strain | 4 | 2012 | 170 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2011 | 142 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2173 | 0.100 |
Why?
|
| Pneumonectomy | 3 | 2022 | 831 | 0.100 |
Why?
|
| Cell Polarity | 1 | 2012 | 208 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 6009 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2019 | 4804 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2021 | 2967 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 272 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2011 | 229 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 984 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 125 | 0.090 |
Why?
|
| Genes, ras | 2 | 2012 | 667 | 0.090 |
Why?
|
| Apoptosis | 4 | 2020 | 7591 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2022 | 209 | 0.090 |
Why?
|
| Thoracotomy | 2 | 2022 | 220 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2307 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 1688 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2019 | 479 | 0.090 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 13658 | 0.080 |
Why?
|
| Thiazoles | 1 | 2013 | 726 | 0.080 |
Why?
|
| Cytokines | 4 | 2020 | 2809 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2023 | 32848 | 0.080 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 276 | 0.080 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 318 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 15694 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3203 | 0.080 |
Why?
|
| Gene Expression | 3 | 2017 | 3570 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 3022 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 470 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2045 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2022 | 1053 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2017 | 235 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10035 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2013 | 3536 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2023 | 4078 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 650 | 0.070 |
Why?
|
| Fibrosis | 2 | 2020 | 793 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 3639 | 0.060 |
Why?
|
| Biomarkers | 4 | 2017 | 5047 | 0.060 |
Why?
|
| Pyrazines | 2 | 2019 | 495 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 2 | 2018 | 216 | 0.060 |
Why?
|
| Cancer Care Facilities | 2 | 2019 | 884 | 0.060 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2003 | 124 | 0.060 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2023 | 33 | 0.060 |
Why?
|
| Hematoxylin | 1 | 2023 | 34 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2017 | 1648 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2003 | 51 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2015 | 5637 | 0.060 |
Why?
|
| Sucrose | 1 | 2003 | 64 | 0.060 |
Why?
|
| Phenotype | 3 | 2021 | 6295 | 0.060 |
Why?
|
| CD27 Ligand | 1 | 2023 | 25 | 0.060 |
Why?
|
| Dimerization | 1 | 2003 | 304 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 600 | 0.050 |
Why?
|
| Genetic Techniques | 1 | 2003 | 130 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 1678 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 706 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2023 | 177 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2023 | 182 | 0.050 |
Why?
|
| Receptors, Histamine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 2508 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2023 | 557 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2015 | 626 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6207 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2003 | 627 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.050 |
Why?
|
| Genotype | 2 | 2020 | 4109 | 0.050 |
Why?
|
| Alpha-Globulins | 1 | 2021 | 14 | 0.050 |
Why?
|
| Discoidin Domain Receptor 2 | 1 | 2021 | 10 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 255 | 0.050 |
Why?
|
| Secretory Vesicles | 1 | 2021 | 39 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 10001 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2021 | 56 | 0.050 |
Why?
|
| Liposomes | 1 | 2003 | 684 | 0.050 |
Why?
|
| Young Adult | 1 | 2020 | 21445 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 80 | 0.050 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2020 | 41 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 4844 | 0.050 |
Why?
|
| Cell Line | 2 | 2012 | 5114 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.050 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2020 | 29 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 5539 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 434 | 0.050 |
Why?
|
| Jagged-2 Protein | 2 | 2011 | 12 | 0.050 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2020 | 113 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 223 | 0.050 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 100 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 1487 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 4988 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2021 | 602 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2017 | 4233 | 0.040 |
Why?
|
| Biological Transport | 1 | 2021 | 597 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2018 | 6150 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 124 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 326 | 0.040 |
Why?
|
| Carcinogens | 1 | 2020 | 384 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2015 | 677 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 141 | 0.040 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 388 | 0.040 |
Why?
|
| Adolescent | 1 | 2020 | 31252 | 0.040 |
Why?
|
| Pyrazoles | 2 | 2019 | 1471 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2023 | 834 | 0.040 |
Why?
|
| Genes, p53 | 2 | 2014 | 1090 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2016 | 1385 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 289 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 555 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1163 | 0.040 |
Why?
|
| Peptides | 2 | 2017 | 1479 | 0.040 |
Why?
|
| Cell Communication | 1 | 2021 | 509 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 942 | 0.040 |
Why?
|
| Lentivirus | 1 | 2018 | 169 | 0.040 |
Why?
|
| Texas | 2 | 2019 | 6311 | 0.040 |
Why?
|
| Ligands | 2 | 2011 | 995 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 550 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 703 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2020 | 668 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 1048 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3101 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 2315 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 1618 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 226 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 1026 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 6942 | 0.040 |
Why?
|
| Integrases | 1 | 2018 | 262 | 0.040 |
Why?
|
| Phenols | 1 | 2017 | 107 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 182 | 0.040 |
Why?
|
| CD57 Antigens | 1 | 2016 | 20 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 1489 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2020 | 825 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2017 | 159 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 607 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 134 | 0.030 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 122 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 1099 | 0.030 |
Why?
|
| Pteridines | 1 | 2015 | 34 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2020 | 677 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 716 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 314 | 0.030 |
Why?
|
| Macrophages | 1 | 2021 | 1304 | 0.030 |
Why?
|
| Software | 1 | 2022 | 1321 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 218 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2139 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 12873 | 0.030 |
Why?
|
| Thiophenes | 1 | 2015 | 148 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 233 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 133 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 1301 | 0.030 |
Why?
|
| Gonanes | 1 | 2014 | 45 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 278 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1823 | 0.030 |
Why?
|
| Thymine Nucleotides | 1 | 2013 | 17 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 582 | 0.030 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1994 | 132 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2014 | 292 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 5673 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2013 | 85 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2018 | 1694 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 252 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 3890 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2021 | 2022 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 336 | 0.030 |
Why?
|
| Discs Large Homolog 1 Protein | 1 | 2012 | 9 | 0.030 |
Why?
|
| Immunity | 1 | 2014 | 342 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1681 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Myosins | 1 | 2012 | 96 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 2216 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 4298 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 2011 | 105 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1994 | 614 | 0.030 |
Why?
|
| Doxycycline | 1 | 2012 | 178 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 1442 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2011 | 110 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1165 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 445 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 177 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 703 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 1399 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2018 | 1664 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2011 | 146 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 612 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 342 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 413 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 429 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 798 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 997 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 423 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Metabolomics | 1 | 2013 | 478 | 0.020 |
Why?
|
| Dasatinib | 1 | 2013 | 862 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2011 | 388 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 343 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 2086 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2009 | 85 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2009 | 93 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1338 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 368 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 1519 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2009 | 101 | 0.020 |
Why?
|
| DNA Replication | 1 | 2013 | 744 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 1271 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2013 | 1113 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 615 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 769 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 7551 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 6089 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2009 | 461 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 1064 | 0.020 |
Why?
|
| Myocardium | 1 | 1994 | 1313 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2011 | 747 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2074 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 1763 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 17523 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2171 | 0.020 |
Why?
|
| United States | 1 | 2023 | 15433 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 12926 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6869 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 4917 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2054 | 0.020 |
Why?
|
| Hypertension | 1 | 1994 | 1503 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 1533 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 4053 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 2403 | 0.010 |
Why?
|
| Desoxycorticosterone | 1 | 1994 | 16 | 0.010 |
Why?
|
| Macaca | 1 | 1994 | 95 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1994 | 156 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1994 | 562 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 777 | 0.010 |
Why?
|
| Age Factors | 1 | 1994 | 5377 | 0.000 |
Why?
|